Good MorningEquity markets rebounded on Thursday on hopes that labor data would be a Cinderella story. The data can not be too hot or cold or may raise fears of higher interest rates for longer or looming recession, depending on which way the wind blows. In either case, the outcome for the S&P 500 will be tepid earnings growth in 2024. The S&P 500 advanced 0.75% at the session's peak and remains within a tight range at critical resistance.
Next week will be a hot one for traders. The economic calendar is filled with potentially market-moving events running from the Retail Sales figure through inflation and an FOMC policy announcement. What makes next week different from others is that the PPI and CPI will come out ahead of the FOMC decision and could drastically alter the outcome. The data is expected to cool from the previous month; the question is by how much. Enough to put the committed on track to cut rates in early 2024 or enough to cause concern that inflation is falling too fast? Featured: 2023's Best Stock: Buy Before the Market Knows (Darwin) 
|
Stocks | | |
If you're looking to invest in the stock market, you may have heard the term "consumer staples stocks."
But what are consumer staples stocks, and why should you consider adding them to your investment portfolio? We will teach you how and why consumer staples stocks are essential. Plus, we w... Read the Full Story |
|
From Our PartnersLove him or hate him, it’s hard to deny Elon Musk is a genius.
After revolutionizing online payment processing (PayPal), space exploration (SpaceX), and the auto industry (Tesla)...
He’s getting ready to do it again with his new AI venture. | | | | To get all the details, click here. |
|
Stocks | | |
Healthcare is a necessity in our everyday lives. Advancements in medicine and medical treatments have helped people live longer and healthier. While they say you can't put a price on good health, you can invest in it. Healthcare is a big business.
Healthcare is one of the 11 sectors that co... Read the Full Story |
|
Tech | | |
The world of global token exchange (GTE) technology is rapidly making digital exchange easier, cheaper and more secure. Some have designated it "the next big thing," bigger than artificial intelligence or 5G technology.
However, investing in this exciting new area can feel daunting. By the ... Read the Full Story |
|
From Our PartnersAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.*
*Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com | | | | Invest in Autonomix today. |
|
Markets | | | Wall Street rose Thursday to snap its first three-day losing streak since Halloween.The S&P 500 climbed 36.25 points, or 0.8%, to 4,585.59. The Dow Jones Industrial Average added 62.95, or 0.2%, to 36,117.38, and the Nasdaq composite jumped 193.28, or 1.4%, to 14,339.99.Big Tech stocks helped po... Read the Full Story |
|
Stocks | | | Wall Street climbed back to its best level in 20 months on Friday following a stronger-than-expected report on the U.S. job market.The S&P 500 rose 0.4%, enough to clinch a sixth straight winning week for the index, which is its longest such streak in four years. Wall Street’s main measure of he... Read the Full Story |
|
From Our PartnersWhat many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now." | | | | Full details and steps to take here. |
|
Markets | | |
In the 12-year cycle of animals in the Chinese zodiac, 2024 will be the Year of the Dragon. If equity investors get their way, it will be a green dragon.
Barring a big December rally, China’s stock market will finish in the red for the third consecutive year in 2023. Chinese stocks listed i... Read the Full Story |
|
Markets | | | U.S. employers added a healthy 199,000 jobs last month and the unemployment rate fell, fresh signs that the economy could achieve an elusive “soft landing,” in which inflation would return to the Federal Reserve’s 2% target without causing a steep recession Read the Full Story |
|
Markets | | |
The biotech sector, iShares Biotechnology ETF (NASDAQ: IBB), has enjoyed steady buying lately, closing in the green for seven consecutive days. The recent rally comes after the sector ETF broke out of a tight consolidation after sharply bouncing from its 52-week low.
Buyers have stepped in since ... Read the Full Story |
|
Markets | | | Paris Saint-Germain owner Qatar Sports Investments agreed to sell a minority stake to U.S. private equity platform Arctos Partners on Thursday.Financial terms of the deal were not disclosed by the French league club. Arctos will own up to 12.5% of the club, valuing PSG at between 4 billion euros ($4... Read the Full Story |
|
Markets | | | The heads of Wall Street’s biggest banks used an appearance on Capitol Hill to plead with senators to stop the Biden administration’s proposed changes to how banks are regulated, warning that the proposals could negatively impact the economy at a time of geopolitical turmoil and inflation Read the Full Story |
|
Friday's Early Bird Stock Of The Day EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts. | | View Today's Stock Pick |
|
